Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04887532
Other study ID # HR19042-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 1, 2021
Est. completion date July 27, 2021

Study information

Verified date May 2021
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date July 27, 2021
Est. primary completion date July 27, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Age 18 ~ 45 years old, including boundary value; 2. Female subjects weigh =45kg, male subjects weigh =50kg, and body mass index (BMI) is within the range of 19.0~26.0kg/m2 (body mass index = weight (kg)/height 2 (m2)), including boundary values; 3. The subject has no plans to give birth or donate sperm/eggs for at least 3 months from the signing of the informed consent form to the end of the study, and voluntarily take effective non-drug contraceptive measures (including partners) during the trial period; 4. Before the test, learn more about the nature, significance, possible benefits, possible inconvenience and potential risks of the test. Able to understand the procedures and methods of this research, willing to strictly abide by the clinical trial protocol to complete the trial, and voluntarily sign an informed consent form. Exclusion Criteria: 1. People with a known history of drug or food allergies; 2. Past or current history of any disease that may affect the safety of subjects participating in the trial or the internal process of the research drug, including: digestive system, blood system, circulatory system, urinary system, respiratory system, nervous system, immune system, endocrine system, Those with a clear history of mental disorders and metabolic disorders, or other diseases that are not suitable for participating in clinical trials; 3. Those who have used drugs that affect the function of liver metabolic enzyme CYP3A4 within 30 days before the first administration (such as inducers-enzalutamide, mitotane, carbamazepine, phenytoin, rifampin; inhibitors-clarithromycin, irradian) Traconazole, ketoconazole, ritonavir, telithromycin, etc.), or those who have used contraceptives within 30 days before administration; 4. Those who have used any drug within 14 days before the first dose; 5. Those who have taken a special diet (including grapefruit/grapefruit juice, chocolate, food or beverages containing caffeine) within 48 hours before the first administration, or have consumed excessive amounts of tea, coffee or beverages containing caffeine every day for the past 1 month (Average more than 8 cups per day, 200 mL per cup); 6. Participate in drug clinical trials and take trial drugs as subjects within 3 months before screening, or plan to participate in other clinical trials during the study period; 7. Those who donated blood or lost more than 400 mL (excluding menstrual blood loss in women) within 3 months before screening, received blood transfusion or used blood products, or planned to donate blood during the trial period or within 1 month after the end of the trial; 8. Those who have undergone major surgery within 3 months before screening, or plan to undergo surgery during the study period; 9. Those who smoked more than 5 cigarettes a day on average in the 3 months before screening, or who did not agree to ban smoking during the trial; 10. In the 6 months before screening, the average weekly alcohol consumption exceeded 14 units of alcohol (1 unit = 360 mL of beer with 5% alcohol content or 45 mL of spirits with 40% alcohol content or 150 mL of wine with 12% alcohol content), Or those who do not agree to abstain from alcohol during the trial; 11. The results of laboratory tests (blood routine, urine routine, blood biochemistry, blood coagulation function) are judged by clinicians as abnormal and clinically significant; 12. Those whose 12-lead ECG, physical examination or vital signs examination results are judged by clinicians as abnormal and clinically meaningful; 13. Immunological examinations (hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, Treponema pallidum antibody) are positive; 14. Those with abnormal chest radiograph (posterior anterior position) and clinical significance; 15. Women who are pregnant or breastfeeding; 16. Those who have a positive alcohol breath test; 17. Those who have a positive urine drug screening; 18. Those who have a history of drug abuse or drug abuse; 19. People with a history of difficulty in venous blood collection, intolerance to venipuncture, or a history of fainting needles 20. Those who have difficulty swallowing, or have special dietary requirements and cannot follow a uniform diet; 21. The investigator believes that the subject has any other factors that are not suitable for participating in this trial (such as inability to understand the research requirements, poor compliance, infirmity, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HR19042 capsule
phase 1 :8mg; phase 2:12mg; phase 3:16mg

Locations

Country Name City State
China Shanghai Xuhui Central Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Peak concentration of drug observed from 0 hour to 24 hours after administration 0-24 hours
Primary AUC0-t; The area under the drug concentration-time curve at the sample collection time t that can be accurately determined from 0 hour to 24 hours after administration 0-24 hours
Primary AUC0-8 The area under the concentration-time curve of drug from 0 hour to infinity after administration 0 hour to 24 hours
Secondary AE Adverse event Screening period to end of follow-up period, approximately 1 month
Secondary the change of blood cortisol AUC0-24h from baseline after each cycle of administration 0-24 hours
See also
  Status Clinical Trial Phase
Completed NCT03643965 - Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Phase 3
Recruiting NCT04557462 - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy Phase 3
Active, not recruiting NCT04541043 - Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) Phase 3
Recruiting NCT05847920 - Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy Phase 2
Recruiting NCT02765594 - Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Phase 4
Not yet recruiting NCT02712697 - Integrative Medicine of IgA Nephropathy N/A
Not yet recruiting NCT06137768 - A Trial of HRS-5965 Tablets in Primary IgA Nephropathy Phase 2
Completed NCT02351752 - Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Phase 4
Completed NCT04014335 - A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy Phase 2
Completed NCT01738035 - The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Phase 2
Recruiting NCT05797610 - A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Phase 3